Obparp 100mg Tablet

Obparp 100mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

• Nausea
  
• Vomiting
  
• Fatigue
  
• Diarrhea
  
• Loss of appetite
  
• Anemia (low number of red blood cells)
  
• Headache
  
• Decreased blood cells (red cells, white cells, and platelets)
  
• Taste change
  
• Cough
  
• Breathlessness
• Indigestion
  
• Abdominal pain

Contact your healthcare provider if you face any unusual or persistent side effects.

Take Obparp 100mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results. It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.

Obparp 100mg Tablet is a prescription based anticancer medicine with Olaparib (100mg) as an active ingredient. It works by blocking the action of an enzyme known as PARP, that helps to fix damaged DNA.

As a result by stopping the action of PARP, Lupiparp prevents cancer cells from repairing themselves, which cause them to die off & slowing tumor growth. Also it can decrease tumor growth in both as monotherapy or following chemotherapy.

• Robert, M., Frenel, J. S., Gourmelon, C., Patsouris, A., Augereau, P., & Campone, M. (2017). Olaparib for the treatment of breast cancer. Expert opinion on investigational drugs, 26(6), 751-759 - https://pubmed.ncbi.nlm.nih.gov/28395540/
  
• Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533 - https://pubmed.ncbi.nlm.nih.gov/28578601/
  
• Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018). Olaparib for the treatment of breast cancer. Expert review of anticancer therapy, 18(6), 519-530.
  
• Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., ... & Harter, P. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416-2428.
  
• Bixel, K., & Hays, J. L. (2015). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
  
• Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., ... & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505.​